Джейн Плант - Антирак груди

Gaull, G.E. and others, 1985. Significance of growth modulators in human milk. Pediatrics , 75 (2), 142–145.

Delgrange, E. and others, 1997. Sex related differences in the growth of prolacrinomas: a clinical and proliferation marker study. Journal of Clinical Endocrinology and Metabolism . 82 (7), 2102–2107.

Vonderhaar, B.K., 1998, Prolactin: The forgotten hormone of human breast cancer. Pharmacology and Therapeutics , 79 (2), 169–178; Das, R. and others; 1996. Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells. Oncogene , 13 (6), 1139–1145; Mershon, J, and others, 1995. Prolactin is a local growth factor in rat mammary tumors. Endocrinology , 136 (8), 3619–3623; Ginsberg, E. and others, 1995. Prolactin secretion by human breast cancer cells. Cancer Res , 55 (12), 2591–2595; Fuh, G. and others, 1995. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J. Biol Chem , 270 (22), 13 133-13 137.

Leav, I. and others, 1999. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. American Journal of Pathology , 154 (3), 863–870; Horti, J. and others, 1998. A phase 2 study of bromocriptine in patients with androgen-independent prostate cancer. Oncology Reports , 5 (4), 893–896; Franklin, R.B. and others, 1997. Prolactin regulation of mitochondrial aspartate aminotransferase and proteinkinase C Molecular and Cellular Endocrinology , 127 (1), 19–25; Janssen, T. and others, 1996. In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Cancer , 77 (1), 144–149; Janssen, T. and others, 1995. Organ culture of human tissue as study model of hormonal and pharmacological regulation of benign prostatic hyperplasia and of prostatic cancer, (frans) Acta Urol Belg , 63 (1), 7-14; Oliver, R.T. and others, 1995. New directions with hormone therapy in prostate cancer: possible benefit from blocking prolactin and use of hormone treatment intermittently in combination with immunotherapy. Eur. J. Cancer , 31A (6), 859–860; Rana, A. and others, 1995. A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate. Eur. J. Cancer , 31A (6), 871–875.

Hinuma, S. and others, 1998. A prolactin-releasing peptide in the brain. Nature , 393 (6682), 272–276.

Smith, S.S. and others, 1986. Presence of luteinising hormonereleasing hormone (LHRH) in milk. Endocrinol Exp., 2 °C2-3), 147–153; Koldovsky, O., 1989. Search for the role of milk borne biologically active peptides for the suckling. J.Nutr., 119 (II), 1543–1551; Nair, R.M. and others, 1987. Studies on LHRH and physiological fluid amino acids in human colostreum and milk. Endocrinolologia Experimentalis , 21 (1), 23–30.

White, M.E. and others, 1986. Milk progesterone concentrations following simultaneous administration of buserelin and cloprostenol in cattle with normal corporal lutea. Canadian Journal of Veterinary Research , 50 (2), 285–286; Dinsmore, R.P. and others, 1989. Effect of gonadotropin-releasing hormone on clinical response and fertility in cows with cystyic ovaries, as related to milk progesterone concentration and days after partarition. Journal of the American Veterinary Medical Association, 195 (3), 327–330.

Berseth, C.I. and others, 1990. Postpartum changes in pattern of gastrointestinal regulatory peptides in human milk. Am. J. Clin. Nutr., 51 (6), 985–990.

Berseth, C.I. and others, 1990. Postpartum changes in pattern of gastrointestinal regulatory peptides inhuman milk. Am. J. Clin. Nutr., 51 (6), 985–990.

Flood, J.F. and others, 1991. Increased food intake by neuropeptide Y is due to an increased motivation to eat. Peptides , 12 (6), 1329–1332.

Amarant, T. and others, 1982. Luteinising hormone-releasing hormone and thyrotropin-releasing hormone in human and bovine milk. European Journal of Biochemistry , 127 (3), 647–650; Baram, T and others, 1977. Gonadotropin-releasing hormone in milk. Science , 198 (4314), 300–302.

Koike, K. and others, 1997. The pituitary folliculo-stellate cell line TtT/GF augments basal and TRH-inducedprolactin secretion by GH3 cells. Life Sci , 61 (25), 2491–2497; Tyson, J.E. and others, 1975. The influence of prolactine secretion on human lactation. J. Clin. Endocrinol Metab , 40 (5), 764–773.

Grochowska, R. and others, 1999. Stimulated growth hormone (GH) release in Friesian cattle with respect to GH genotypes. Reproduction Nutrition Development , 39 (2), 171–180; Bourne, R.A. and others, 1977. Serum growth hormone concentrations after growth hormone or thyroid-releasing hormone in cows. Journal of Dairy Science , 60 (10), 1629–1635.

Chomczinsky, P. and others, 1993. Stimulatory effect of thyroid hormone on growth hormone gene expression in a human pituitary cell line. J. Clin. Endocrinol Metab , 77 (1), 281–285; Reynolds, A.M., 1991. The effects of chronic exposure to supra physiological concentrations of 3,5,3-triiodo-L-thyronine (T3) on cultured GC cells. Journal of Cellular. Physiology , 149 (3), 544–547.

Tenore, A. and others, 1980. Thyroidal response to peroral TSH in suckling and weaned rats. American Journal of Physiology , 238 (5), E428-430.

Slebodzinski, A.B. and others, 1998. Triiodothyronine (T3), insulin and characteristics of 5'-monodiodinase (5'-MD) in mare's milk from partarition to 21 days post-partum. Reproduction Nutrition Development , 38 (3), 235–244.

Fujimoto, N. and others, 1997. Upregulation of the estrogen receptor by triiodothyronine in rat pituitary cell lines. Journal of Steroid Biochemistry and Molecular Biology , 61 (1–2), 79–85.

Koldovsky, O., 1989. Search for the role of milk borne biologically active peptides for the suckling. J. Nutr., 119 (11), 1543–1551; Buts, J.P., 1998. Bioactive factors in milk. (in French.) Arch Pediatr , 5 (3), 298–306.

Faulkner, A., 1998. Insulin-like growth factor concentrations in milk and plasma after growth hormone treatment. Biochemical Society Transactions , 26 (4), S386; Baldini, E. and others, 1994. In vivo cytokinetic effects of recombinant human growth hormone (rhGH) in patients with advanced breast carcinoma. Journal of Biological Regulators and Homeostatic Agents , 8 (4), 113–116; Scheven, B.A. and others, 1991. Effects of recombinant human insulin-like growth factor-1 and -2 (IGF) and growth hormone (GH) on the growth of normal adult human osteoblast-like cells and human osteogenic sarcoma cells. Growth Regulation , 1 (4), 160–167; Hodate, K. and others, 1990, Plasma growth hormone, insuline-like growth factor-l, and milk production response to exogenous human growth hormone-releasing factor analogs in dairy cows. Endocrinologia Japonica , 37 (2), 261–273.

Koldovsky, O., 1989. Search for the role of milk borne biologically active peptides for the suckling. J. Nutr., 119 (11), 1543–1551; Buts, J.P., 1998. Bioactive factors in milk. (in French.) Arch Pediatr , 5 (3), 298–306.

Westrom, B.R. and others, 1987. Levels of immunoreactive insulin, neurotensin, and bombesin in porcine colostreum and milk. J. Pediatr. Gastroenterol. Nutr., 6 (3), 460–465; Ehman, R. and others, 1985. Bombesin, neurotensin and pro-gamma-melanotropin in immunoreactants in human milk. Regulatory Peptides , 10 (2–3), 99-105.

Shutt, D.A. and others, 1985. Comparison of total and free cortisol in bovine serum and milk colostreum. J. Dairy Set , 68 (7), 1832–1834.

Vaarala, O. and others, 1998. Cow milk feeding induces antibodies to insulin in children – a link: between cow milk and insulin-dependent diabetes mellitus? Scandinavian Journal of Immunology 47 (2), 131–135; Slebodzinsky, A.B. and others, 1998. Triiodothyronine (T3), insulin and characteristics of 5'-monodiodinase (5'-MD) in mare's milk from partarition to 21 days post-partum. Reprod Nutr Dev , 38 (3), 235–244; Westrom, B.R. and others, 1987. Levels of immunoreactive insulin, neurotensin, and bombesin in porcine colostreum and milk. J. Pediatr Gastroenterol Nutr., 6 (3), 460–465.

Ferrando, T. and others, 1990. Beta-endorphin-like and alpha-MSH-like immunoreactivities in human milk. Life Sci , 47 (7), 633–635.

http://www.13.waisays.com/cancer2.htm; Newcomb, P.A. and Egan, K.M., 2006. Dairy food and ovarian cancer risk. The Lancet , March 2006, 797–799; Stang, A. and others, 2006. Adolescent milk fat and galactose consumption and testicular germ cell cancer. Cancer Epidemiology and Biomarkers Prevention , 15, 2189–2195.

Maruuchi, T. and others, 1998. Effects of gonadotropin-releasing hormone agonist on rat ovarian adenocarcinoma cell lines in vitro and in vivo. Japanese Journal of Cancer Research , 89 (9), 977–983; Kuroda, H. and others, 1998. Human chorionic gonadotrophin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of up-regulation of IGF-1 by hCG. Int J. Cancer , 76 (4), 571–578; Kurbacher, C.M. and others, 1995. Influence of luteinising hormone on cell growth and CA 125 secretion of primary epithelial ovarian carcinomas in vitro. Tumour Biology , 16 (6), 374–384; Manetta, A. and others, 1995. Inhibition of growth of human ovarian cancer in nude mice by luteinising hormone-releasing hormone antagonist Cetrorelix (SB-75). Fertility and Sterility , 63 (2), 282–287.

Reiter, E. and others, 1999. Effects of pituitary hormones on the prostate. Prostate , 38 (2), 159–165; Lamharzi, N. and others, 1998. Luteinising hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF– 2 in tumors. Regulatory Peptides , 77 (113), 185–192; Jungwirth, A. and others, 1997. Luteinising hormone-releasing hormone (LH-RH) antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-2 inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate , 32 (3), 164–172; Maezawa, H. and others, 1997. Potentiating effect of buserelin acetate, an LHRH agonist on the proliferation of ventral prostatic epithelial cells in testosterone-treated castrated rats. Int J. Urol , 4 (4), 411–416; Using, A.W. and others, 1993. Serological precursors of cancer serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev , 2 (1), 27–32; Garde, S. and others, 1993. Effect of prostatic inhibiting peptide on prostate cancer cell growth in vitro and in vivo. Prostate , 7 (2), 183–194.